Prevnar-13 Vaccine Response in Aging HIV Patients

Phase 4

Recruiting

Led By Edward N Janoff, MD

Research Sponsored by VA Eastern Colorado Health Care System

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 21-45 or 55-75 Years Old

Have not received pneumococcal vaccine Prevnar PCV-13

Timeline

Screening 3 weeks

Treatment Varies

Follow Up a change from baseline, measured at pre-vaccination, and 1 month post vaccine

Awards & highlights

Study Summary

This trial looks at HIV-1, aging, & their impact on infection risk & vaccine response.

Who is the study for?

This trial is for veterans aged 21-45 or 55-75 with HIV but no history of serious infections, who haven't had the Prevnar PCV-13 vaccine. Participants must have an undetectable viral load and be able to attend a few study visits over a month. Those with chronic kidney disease, active liver issues, no spleen, or on certain medications like steroids or immunosuppressants can't join.Check my eligibility

What is being tested?

The study aims to understand how HIV and aging affect the body's response to the Prevnar 13 vaccine, which helps prevent pneumonia and other diseases caused by pneumococcal bacteria.See study design

What are the potential side effects?

While not specified here, common side effects of vaccines like Prevnar may include pain at injection site, fatigue, headache, muscle pain, joint pain, decreased appetite among others.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 21-45 or 55-75 years old.

Select...

I have not received the Prevnar PCV-13 pneumococcal vaccine.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ a change from baseline, measured at pre-vaccination, and 1 month post vaccine

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~a change from baseline, measured at pre-vaccination, and 1 month post vaccine

This trial's timeline: 3 weeks for screening, Varies for treatment, and a change from baseline, measured at pre-vaccination, and 1 month post vaccine for reporting.